STATEMENT OF NEED
An estimated 72,240 new cases of non-Hodgkin lymphoma are diagnosed in the United States annually. Approximately 30% are classified as DLBCL, which is a very aggressive variant with multiple subtypes. Although the clinical outcomes of patients with DLBCL have improved during the past decade, approximately one-third develop relapsed or refractory disease, representing a significant cause of morbidity and mortality. The prognosis of patients with DLBCL remains poor, with a 5-year overall survival rate of only 33%.
Hematology/oncology physicians, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with diffuse large B-cell lymphoma.
Upon completion of this activity, participants should be able to:
- Assess prognostic markers to refine treatment planning for individual patients with DLBCL
- Evaluate efficacy and safety data on novel therapeutic regimens for relapsed/refractory DLBCL
- Apply posttreatment monitoring strategies to ensure optimal outcomes for patients with DLBCL
Stephen J. Schuster, MD (Chairperson)
Robert and Margarita Louis-Dreyfus Professor in CLL Clinical Care and Research
University of Pennsylvania Perelman School of Medicine
Jia Ruan, MD, PhD
Associate Professor of Clinical Medicine
Weill Cornell Medicine
Christopher R. Flowers, MD, MS
Director, Lymphoma Program
Professor of Hematology and Oncology
There is no fee to participate in or claim CME credit for this activity.
Please note that the University of Cincinnati and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Cincinnati and i3 Health. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits. The University of Cincinnati will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The University of Cincinnati does not endorse any products or services.
Stephen J. Schuster, MD discloses that he has served on the advisory board/consulted for Celgene, Genentech, Gilead, Merck, Nordic Nanovector, Novartis, and Seattle Genetics. He has received grants/research support from Adaptive, BMS, Celgene, Genentech, Hoffmann-LaRoche, Janssen R&D, Merck, and Novartis.
Jia Ruan, MD, PhD discloses that she has served on the advisory board for AstraZeneca/Acerta, Celgene, Pharmacyclics/Janssen, and Seattle Genetics. She has served as a consultant for Celgene. She has received grants/research support from Celgene, Pharmacyclics/Janssen, and Seattle Genetics.
Christopher R. Flowers, MD, MS discloses that he has consulted for AbbVie, Bayer, Celgene, Denovo Biopharma, Genentech/Roche, Gilead, Karyopharm, OptumRx, Pharmacyclics/Janssen, and Spectrum. He has received grants/research support from AbbVie, Acerta, Celgene, Genentech/Roche, Janssen, Millenium/Takeda, and TG Therapeutics.
University of Cincinnati staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of Cincinnati, Office of Continuing Medical Education.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
The University of Cincinnati and i3 Health require CME/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Kite Pharma, Inc.